Wave Life Sciences Ltd (WVE)

May 25, 2026

Should WVE-006’s RNA-Editing AAT Data Shift the Risk-Reward Calculus for Wave Life Sciences (WVE) Investors? - Yahoo Finance

May 25, 2026

May 23, 2026

Wave Life Sciences (WVE) Valuation Check After Sharp Share Price Weakness - simplywall.st

May 23, 2026

May 22, 2026

WAVE Life Sciences Analyst Ratings and Price Targets | NASDAQ:WVE - Benzinga

May 22, 2026

May 22, 2026

WVE Stock Price, Quote & Chart | WAVE LIFE SCIENCES LTD (NASDAQ:WVE) - ChartMill

May 22, 2026

May 21, 2026

Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $14 - Moomoo

May 21, 2026

May 20, 2026

Wave Life Sciences (WVE) Is Down 11.4% After Positive WVE-006 AATD Data and Accelerated Path Update - simplywall.st

May 20, 2026

May 20, 2026

Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data - Seeking Alpha

May 20, 2026

May 20, 2026

WVE Maintained by Wells Fargo -- Price Target Raised to $14.00 - GuruFocus

May 20, 2026

May 20, 2026

Wave Life Sciences Is Maintained at Overweight by Wells Fargo - Moomoo

May 20, 2026

May 20, 2026

CCORF Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $43 - Moomoo

May 20, 2026

May 20, 2026

WVE: Advancing siRNA and RNA editing therapies with strong clinical data and regulatory momentum - TradingView

May 20, 2026

May 20, 2026

Wells Fargo raises Wave Life Sciences price target on AATD data - Investing.com Australia

May 20, 2026

May 20, 2026

Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $14 - Moomoo

May 20, 2026

May 20, 2026

Wave Life Sciences Signals Momentum in Earnings Call - TipRanks

May 20, 2026

May 19, 2026

Wave Life Sciences crashes deep into oversold territory as obesity drug data disappoints. Should you buy the dip? - MSN

May 19, 2026

May 19, 2026

WVE Maintained by HC Wainwright & Co. -- Price Target Lowered to $13 - GuruFocus

May 19, 2026

May 19, 2026

Wave Life Sciences' New Data From AATD Study Met Expectations, Wedbush Says - Moomoo

May 19, 2026

May 19, 2026

Cantor Fitzgerald reiterates Overweight on Wave Life Sciences stock By Investing.com - Investing.com South Africa

May 19, 2026

May 19, 2026

Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 - Yahoo Finance UK

May 19, 2026

May 19, 2026

A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $13 to $15 - Moomoo

May 19, 2026

May 19, 2026

Wave Life Sciences stock price target lowered to $13 by H.C. Wainwright - Investing.com South Africa

May 19, 2026

May 19, 2026

Cantor Fitzgerald reiterates Overweight on Wave Life Sciences stock - Investing.com

May 19, 2026

May 19, 2026

H.C. Wainwright Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $13 - Moomoo

May 19, 2026

May 19, 2026

Wave Life Sciences Announces Positive RestorAATion-2 Trial Results for WVE-006, a Novel RNA Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) - Minichart

May 19, 2026

May 18, 2026

Wave Life Sciences Ltd. (WVE) Shareholder/Analyst CallSlideshow (NASDAQ:WVE) 2026-05-18 - Seeking Alpha

May 18, 2026

May 18, 2026

WVE: WVE-006 delivers robust Z-AAT reduction and M-AAT restoration with strong safety in PiZZ AATD - TradingView

May 18, 2026

May 18, 2026

Wave Life Sciences reports phase 1b/2a trial data for AATD therapy By Investing.com - Investing.com South Africa

May 18, 2026

May 18, 2026

WVE: WVE-006 delivers robust, durable AAT correction and dynamic response in ZZ AATD with strong safety - TradingView

May 18, 2026

May 18, 2026

WVE Stock Edges Up After Positive Early Data For Rare Disease Drug - Stocktwits

May 18, 2026

May 18, 2026

WVE: WVE-006 achieved up to 71% Z-AAT reduction and restored protective M-AAT levels in AATD - TradingView

May 18, 2026

May 18, 2026

Wave Life Sciences advances WVE-006 RNA editing trial - TipRanks

May 18, 2026

May 18, 2026

Wave Life Sciences (WVE) Reports Progress on WVE-006 in Clinical Trial - GuruFocus

May 18, 2026

May 18, 2026

Wave Life Sciences reports phase 1b/2a trial data for AATD therapy - Investing.com

May 18, 2026

May 18, 2026

Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing - TradingView

May 18, 2026

May 18, 2026

WVE-006 AATD trial shows strong biomarker gains for Wave Life Sciences (WVE) - Stock Titan

May 18, 2026

May 18, 2026

Wave Life Sciences Reports Promising Data for WVE-006 in Treating Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency, Anticipates FDA Feedback in Mid-2026 - Quiver Quantitative

May 18, 2026

May 18, 2026

Experimental RNA-editing shot aims to treat lung and liver damage in alpha-1 - Stock Titan

May 18, 2026

May 17, 2026

Wave Life Sciences (WVE) price target decreased by 15.26% to 23.97 - MSN

May 17, 2026

May 17, 2026

Wave Life Sciences Ltd.Ordinary Shares (NQ: WVE - FinancialContent

May 17, 2026

May 15, 2026

Wedbush Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $15 - Moomoo

May 15, 2026

May 15, 2026

Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says - Moomoo

May 15, 2026

May 14, 2026

Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - GlobeNewswire Inc.

May 14, 2026

May 14, 2026

Wave Life Sciences stock (SG1V20936237): Starts Phase 1 trial for one-time GLP-1 gene therapy - AD HOC NEWS

May 14, 2026

May 14, 2026

Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times

May 14, 2026

May 13, 2026

Adage (NASDAQ: WVE) discloses 1,000,000-share stake, 0.53% of class - Stock Titan

May 13, 2026

May 08, 2026

Wave Life Sciences (WVE) Attracts Positive Attention Amid Compet - GuruFocus

May 08, 2026

May 08, 2026

Surging Q1 Revenue And Narrower Losses Might Change The Case For Investing In Wave (WVE) - Sahm

May 08, 2026